Management of Patients with High-risk Localised, Locally Advanced, and Biochemically Recurrent Prostate Cancer: Report from the 2026 Advanced Prostate Cancer Consensus Conference
Publication date: Available online 27 October 2026 Source: European Urology Author(s): Silke Gillessen, Fabio Turco, Ian D. Davis, Jason A. Efstathiou, Louise Emmett, Karim Fizazi, Nicholas D. James, Neal Shore, Eric J. Small, Matthew Smith, Christopher J. Sweeney, Bertrand F. Tombal, Jochen Walz, Thomas Zilli, Hui-Ming Lin, Martino Pedrani, Marialuisa Puglisi, Vérane Achard, Neeraj Agarwal, Rahul Aggarwal
Management of Patients with High-risk Localised, Locally Advanced, and Biochemically Recurrent Prostate Cancer: Report from the 2026 Advanced Prostate Cancer Consensus Conference. // European Urology. – URL: https://www.sciencedirect.com/science/article/pii/S0302283826024383?dgcid=rss_sd_all
Management of Patients with High-risk Localised, Locally Advanced, and Biochemically Recurrent Prostate Cancer: Report from the 2026 Advanced Prostate Cancer Consensus Conference. European Urology. https://www.sciencedirect.com/science/article/pii/S0302283826024383?dgcid=rss_sd_all
“Management of Patients with High-risk Localised, Locally Advanced, and Biochemically Recurrent Prostate Cancer: Report from the 2026 Advanced Prostate Cancer Consensus Conference.” European Urology.
@article{article45526,
title = {Management of Patients with High-risk Localised, Locally Advanced, and Biochemically Recurrent Prostate Cancer: Report from the 2026 Advanced Prostate Cancer Consensus Conference},
journal = {European Urology},
url = {https://www.sciencedirect.com/science/article/pii/S0302283826024383?dgcid=rss_sd_all}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...